Brink Therapeutics is a Biotechnology Research firm conducting cell therapy research using reprogrammed recombinases.
Brink Therapeutics has raised $4.0M in total funding. The most recent round was Seed. The last funding was announced in April 2025.
Brink Therapeutics's investors include Plug and Play, Kurma Partners, BREEGA, Kima Ventures, AGORANOV.
Brink Therapeutics is headquartered in Paris, France.
Brink Therapeutics is a Biotechnology Research firm conducting cell therapy research using reprogrammed recombinases.
Brink Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Brink Therapeutics — Funding & Investors." VCBacked, April 16, 2025, https://www.vcbacked.co/company/brink-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Brink Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/brink-therapeutics
{{cite web |title=Brink Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/brink-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated